A number of FXR agonists have been developed and tested in clinical trials for the treatment of NASH/NAFLD, in light of the efficacy of the FXR ligands, as a therapy method. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.